Results 121 to 130 of about 14,229 (340)
Myocardial Viability: What We Knew and What Is New
Cardiology Research and Practice, 2012 Some patients with chronic ischemic left ventricular dysfunction have shown significant improvements of contractility with favorable long-term prognosis after revascularization.
Adel Shabana, Ayman El-Menyar
doaj +1 more source
Journal of Pharmacological Sciences, 2011 .: Effects of azelnidipine were examined and compared with those of amlodipine on stunned myocardium in dogs. The left anterior descending (LAD) coronary artery was ligated for 20 min and subsequently released for 60 min.
Seiichiro Kano +3 more
doaj +1 more source
Effects of Endogenous Adenosine and Adenosine Receptor Agonists on Hypoxia-Induced Myocardial Stunning in Guinea-Pig Atria and Papillary Muscles [PDF]
, 2004 Neil M. Gardner +2 more
openalex +1 more source
Myocardial stunning in the neonate
British Journal of Anaesthesia, 1998 the normally oxygenated heart. 9 Myocardial stunning is caused by myocyte dysfunction. Generation of free radicals, resulting in damage to cellular proteins and phospholipids, and disruption of intracellular calcium homeostasis, are the two, non-mutually exclusive mechanismsesponsible forhisost- injury dysfunction.
openaire +2 more sources
SEIZURE-INDUCED MYOCARDIAL STUNNING
Journal of the American College of Cardiology, 2014 A transient LV dysfunction complicating subarachnoid hemorrhage, neurogenic myocardial stunning, has been well described. A similar dysfunction could complicate seizures, a much more prevalent condition, requiring early recognition to prevent complications.
Al-Najafi, Saif, Romanelli, Michael
openaire +1 more source
Interventional therapies for chronic heart failure: An overview of recent developments
ESC Heart Failure, Volume 12, Issue 2, Page 1081-1094, April 2025.Abstract Heart failure (HF), the final manifestation of most cardiovascular diseases, has become a major global health concern, affecting millions of individuals. Despite basic drug treatments, patients present with high morbidity and mortality rates. However, recent advancements in interventional therapy have shown promising results in improving the ...
Bingchen Guo +7 more
wiley +1 more source
Trimetazidine in coronary heart disease patients: mechanism of action and controlled trials’ results
Кардиоваскулярная терапия и профилактика, 2005 Metabolic cardioprotection is an important part of treating patients with coronary heart disease (CHD). The most widely used drug in this group is trimetazidine.
L. V. Kremneva +2 more
doaj
JACC: Basic to Translational Science, 2016 Glucagon-like peptide-1-(7-36) amide (GLP-1) is a human incretin hormone responsible for the release of insulin in response to food. Pre-clinical and human physiological studies have demonstrated cardioprotection from ischemia-reperfusion injury.
Joel P. Giblett, BM, BSc +3 more
doaj +1 more source
Room D, 10/16/2000 2: 00 PM - 4: 00 PM (PS) Naloxone Improves Functional Recovery from Myocardial Stunning in Conscious Dogs [PDF]
, 2000 Maike A. Große Hartlage +4 more
openalex +1 more source
Considerations for drug trials in hypertrophic cardiomyopathy
ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant +17 more
wiley +1 more source